3 ms·
Something some may have missed in the past news flow: > A recent (but not yet peer-reviewed) study of more than half a million U.S. veterans showed that the Jo
by mdp2021 5y ago
Something some may have missed in the past news flow:
> A recent (but not yet peer-reviewed) study of more than half a million U.S. veterans showed that the Johnson & Johnson shot’s protection against infection (whether or not that leads to disease or hospitalization) had plummeted from 88 percent to 3 percent by mid-August, while the other vaccines’ effectiveness had declined much less
Ex https://www.medrxiv.org/content/10.1101/2021.10.13.21264966v1.full.pdf https://www.medrxiv.org/content/10.1101/2021.10.13.21264966v...
...Though
> Paul Offit, who directs the Vaccine Education Center at the Children’s Hospital of Philadelphia, said that J&J may turn out to be “every bit as good as the mRNA vaccines” when compared two doses to two doses. He also suspects that a single dose of J&J would prevent more hospitalizations and deaths than a single dose of Pfizer or Moderna [should not we have data about this latter statement?] [...] thanks to the way it tickles [...] T cells, which help prevent infections from progressing into severe disease. [...] [B]ut some studies have shown that the mRNA vaccines produce T-cell responses with at least as much vigor as J&J’s. [John Moore, microbiology and immunology professor at Weill Cornell Medicine] says that antibodies are a better proxy for protection anyway, and the Moderna and Pfizer options consistently produce more of them in the vaccinated